Published in Am J Kidney Dis on December 01, 2006
CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal (2012) 1.64
Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol (2010) 1.07
Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One (2012) 0.95
Circulating levels of the shed scavenger receptor sCD163 and association with outcome of critically ill patients. J Clin Immunol (2012) 0.89
Immunometabolism in obese asthmatics: are we there yet? Nutrients (2013) 0.86
Metabolic syndrome in peritoneal dialysis patients. NDT Plus (2008) 0.82
Does body fat mass define survival in patients starting peritoneal dialysis? Perit Dial Int (2013) 0.80
Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One (2013) 0.79
Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury: a prospective study. BMC Nephrol (2012) 0.79
Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Clin J Am Soc Nephrol (2016) 0.75
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int (2002) 4.29
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 4.27
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int (2010) 3.53
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol (2008) 2.96
IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int (2005) 2.78
Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int (2003) 2.69
Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood (2009) 2.49
Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol (2008) 2.44
Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int (2005) 2.42
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol (2007) 2.19
Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis (2003) 2.17
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis (2006) 2.09
Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr (2007) 2.07
Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med (2006) 2.06
Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant (2002) 2.05
Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol (2002) 2.03
N‑terminal pro‑B-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn (2015) 2.02
[In Process Citation]. Lakartidningen (2015) 2.01
Identification of the receptor scavenging hemopexin-heme complexes. Blood (2005) 1.97
The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett (2005) 1.96
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant (2007) 1.91
The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood (2003) 1.91
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis (2006) 1.88
CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol (2009) 1.88
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol (2009) 1.84
The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. Nephrol Dial Transplant (2002) 1.82
Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial (2010) 1.82
Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol (2012) 1.80
Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int (2005) 1.80
Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int (2006) 1.80
Physical activity and energy expenditure in haemodialysis patients: an international survey. Nephrol Dial Transplant (2011) 1.74
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology (2014) 1.73
A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl (2003) 1.69
Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial (2002) 1.67
The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant (2006) 1.65
CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal (2012) 1.64
Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant (2008) 1.63
The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant (2004) 1.62